Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company’s last results. The successor of Chris Viehbacher took the opportunity to show the good results made by its Biotech pipeline.
Genzyme, the rare diseases arm of Sanofi, was an important growth driver again this quarter. Total sales of the Rare Diseases franchise were 647 million euros, driven by the sustained success of key brands -Cerezyme, Fabrazyme, and Myozyme- but also the recent launch of Cerdelga, the only first-line oral therapy for Gaucher Disease. In Multiple Sclerosis, Genzyme reported another quarter of exceptional commercial success with over 1 billion euros of sales expected this year.
Sanofi’s growth was also supported by €700 million of sales made by Merial, the Animal Health business of Sanofi which scored its highest quarterly sales ever. The vaccines branch, under Sanofi Pasteur’s flag, came back to growth in the second quarter with sales up to 8.6% led by influenza vaccines and booster vaccines.